Still time to register for this one;
China’s biopharma sector is moving from a sourcing option to a strategic priority for global pharma, with deal structures shifting from single-asset licensing to full platform acquisitions. To help healthcare and life sciences leaders navigate this shift, GlobalData Healthcare, the pharmaceutical and life sciences intelligence arm of GlobalData, a leading intelligence and productivity platform, will host a live webinar on 30 September 2026 3 PM BST / 10 AM EST / 07:30 PM IST exploring the next frontier for China biopharma dealmaking.
The webinar, “The Next Frontier for China Biopharma: From Pipeline Assets to Development Platforms,” builds on GlobalData Healthcare’s recent Intelligence Briefing, “The Two-Way Street: From Stocking the Pipeline to Acquiring Development Platforms,” and its new China Biopharma Maturity Model, a four-stage framework healthcare organizations can use to benchmark their own China readiness.
What the session will cover
Attendees will hear how global pharma is shifting from licensing individual assets to acquiring broader development platforms, what upfront payments and milestone structures reveal about deal value and risk, and how market and competitive intelligence can sharpen partner selection and cross border deal decisions.
Hannah Hans, Head of Pharmaceutical Strategic Intelligence at GlobalData Healthcare, who is chairing the webinar, says: “This is the most exciting moment for pharma BD in a decade, and China is at the center of it. The industry is staring at hundreds of billions in revenue rolling off patent by the end of the decade, pricing pressure in the US is not going away, and internal R&D alone is not refilling those pipelines fast enough. China is where a big share of the answer is coming from. Faster trials, lower cost, and differentiated science.
“GlobalData’s data shows the industry gets it: 58% expect China to be a co-development partner within five years. But only 15% have made it core strategy. Most companies want deeper partnerships with China but are still setting themselves up to do it. That takes leadership-level commitment, backed by the right people, data and deal capability. On the webinar, our panel will discuss the strategic landscape and a China Compatibility framework as well as take a closer look at the deal data.”
Early momentum
The webinar has already attracted strong interest, following engagement with the Intelligence Briefing and coverage from outlets including Healthcare Asia Magazine, PharmaLive and El Español (Invertia), alongside a dedicated podcast episode on GlobalData’s Clinical Trials Arena.
Register now to secure your place for “The Next Frontier for China Biopharma: From Pipeline Assets to Development Platforms,” webinar on 30 September 2026 3 PM BST / 10 AM EST / 07:30 PM IST.
Be the first to comment